GLM1RA is under clinical development by GL Pharm Tech and currently in Phase I for Duodenal Ulcer. According to GlobalData, Phase I drugs for Duodenal Ulcer have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GLM1RA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GLM1RA overview
GLM1RA is under development for the treatment of gastrointestinal (GI) ulcer, duodenal ulcer, cardiovascular disease. It is an incrementally modified drug (IMD). It is administered as oral route.
GL Pharm Tech overview
GL Pharm Tech (GLPHarmTech) is a pharmaceutical company that offers drug formulations and delivery technologies. The company offers modified drugs and generic drugs. It offers products under the brands Zisoren, Kavalin, Relow Pen, Acnon, Parens Enteric, Dinax, Alsaxen, Cesscon, Plan A and Elao. GLPHarmTech’s products are used in the treatment of various therapeutic areas which include melasma, diabetes, emergency contraceptives, birth control, endometriosis, hypertension, benign prostatic hyperplasia (BPH) and hormone replacement therapy (HRT), among others. The company works in collaboration with domestic and foreign pharmaceutical companies. It markets products through its partners and distributors. GLPHarmTech is headquartered in Seongnam, South Korea.
For a complete picture of GLM1RA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
